<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Alpha-PVP - Complete Profile</title>
    <link rel="stylesheet" href="/Dyo-s-Dubious-Domain/style.css">
    <script>
        // Set base path for JavaScript files to use
        window.SITE_BASE_PATH = '/Dyo-s-Dubious-Domain/';
    </script>
</head>

<body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/Dyo-s-Dubious-Domain/" class="site-title">Dyo's Dubious Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/Dyo-s-Dubious-Domain/">Home</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/about/">About</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚Üí <a href="/dyos-domain/stimulants/">Stimulants</a> ‚Üí <span>Alpha-PVP</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>‚ö° Alpha-PVP</h1>
        <h2 class="chemical-name">Œ±-Pyrrolidinopentiophenone</h2>
          
        <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Alpha-PVP" 
                data-category="Stimulants" 
                data-chemical="Œ±-Pyrrolidinopentiophenone">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Slang</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Common Names</h4>
              <span>Œ±-PVP</span> ‚Ä¢ <span>A-PVP</span> ‚Ä¢ <span>Alpha-Pyrrolidinopentiophenone</span> ‚Ä¢ <span>Flakka</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>Flakka</span> ‚Ä¢ <span>Gravel</span> ‚Ä¢ <span>Zombie Drug</span> ‚Ä¢ <span>$5 Insanity</span> ‚Ä¢ <span>Bath Salts</span>
            </div>
            <div class="name-category">
              <h4>Research Names</h4>
              <span>PV-8</span> ‚Ä¢ <span>Prolintanone</span> ‚Ä¢ <span>O-2387</span> ‚Ä¢ <span>1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one</span>
            </div>
            <div class="name-category">
              <h4>Chemical Abbreviations</h4>
              <span>Œ±-PVP-HCl</span> ‚Ä¢ <span>A-PVP hydrochloride</span> ‚Ä¢ <span>Cathinone derivative</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category stimulant danger">Stimulant</span>
          <span class="legal-status schedule-1">Schedule I</span>
          <span class="duration short">2-6 hours</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/assets/substances/alpha-pvp.jpg" alt="Alpha-PVP crystals" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇÅ‚ÇÖH‚ÇÇ‚ÇÅNO</p>
            <p>MW: 231.33 g/mol</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pure-form">
          <h4>Pure Œ±-PVP (HCl salt)</h4>
          <ul>
            <li><strong>Appearance:</strong> White to off-white crystalline powder or chunky crystals</li>
            <li><strong>Texture:</strong> Fine powder or larger crystal chunks ("gravel")</li>
            <li><strong>Odor:</strong> Chemical, slightly fishy or ammonia-like</li>
            <li><strong>Taste:</strong> Extremely bitter, numbing, caustic</li>
            <li><strong>Solubility:</strong> Highly soluble in water and alcohol</li>
            <li><strong>Melting point:</strong> ~140-145¬∞C</li>
          </ul>
        </div>
        
        <div class="street-forms">
          <h4>Street Forms</h4>
          <ul>
            <li><strong>Crystal chunks:</strong> Clear to white "gravel" pieces, often called "flakka"</li>
            <li><strong>Fine powder:</strong> White to tan powder, often cut with other substances</li>
            <li><strong>Pressed tablets:</strong> Less common, may be sold as other stimulants</li>
            <li><strong>Liquid solutions:</strong> Dissolved in e-cigarette liquid for vaping</li>
            <li><strong>Colored variants:</strong> Pink, blue, or other colors from manufacturing impurities</li>
          </ul>
        </div>
        
        <div class="adulterants-warning">
          <h4>‚ö†Ô∏è Common Adulterants & Misrepresentations</h4>
          <p><strong>Adulterants:</strong> Caffeine, lidocaine, mannitol, lactose, inositol</p>
          <p><strong>Related cathinones:</strong> Often mixed with or sold as 4-MMC, 3-MMC, methylone</p>
          <p><strong>Dangerous misrepresentation:</strong> Sold as cocaine, MDMA, or methamphetamine</p>
          <p><strong>Bath salt mixtures:</strong> Combined with other synthetic cathinones</p>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      <div class="dosage-chart">
        <div class="dose-range threshold">
          <span class="range-label">Threshold</span>
          <span class="dose-amount">2-5mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range light">
          <span class="range-label">Light</span>
          <span class="dose-amount">5-10mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range common">
          <span class="range-label">Common</span>
          <span class="dose-amount">10-25mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range strong">
          <span class="range-label">Strong</span>
          <span class="dose-amount">25-50mg</span>
          <div class="dose-bar"></div>
        </div>
        <div class="dose-range heavy">
          <span class="range-label">Dangerous</span>
          <span class="dose-amount">50mg+</span>
          <div class="dose-bar"></div>
        </div>
      </div>
      
      <div class="dosage-by-route">
        <h4>Route-Specific Dosing</h4>
        <ul>
          <li><strong>Oral:</strong> 5-25mg (longer duration, less intense)</li>
          <li><strong>Insufflated:</strong> 3-15mg (faster onset, caustic to nasal tissue)</li>
          <li><strong>Vaporized:</strong> 2-10mg (immediate onset, very short duration)</li>
          <li><strong>IV/IM:</strong> Extremely dangerous - high overdose and psychosis risk</li>
        </ul>
      </div>
      
      <div class="dosage-details">
        <h4>Critical Dosage Warnings</h4>
        <ul>
          <li><strong>Extremely potent:</strong> Active at milligram doses - easy to overdose</li>
          <li><strong>Compulsive redosing:</strong> Strong urge to redose frequently</li>
          <li><strong>Rapid tolerance:</strong> Develops within hours, leading to escalation</li>
          <li><strong>Psychosis threshold:</strong> Risk increases dramatically above 25mg</li>
          <li><strong>Individual variation:</strong> Some users experience psychosis at low doses</li>
        </ul>
      </div>
      
      <p class="dosage-note"><strong>Extreme Danger:</strong> Œ±-PVP is notoriously unpredictable. Psychotic episodes, hyperthermia, and death have occurred at various doses. This substance has an extremely narrow margin between effects and toxicity.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline (varies significantly by route)</h4>
        <div class="timeline-item">
          <span class="time">T+0:01-0:10</span>
          <span class="effect">Onset - Immediate rush (vaporized), intense stimulation</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+0:10-2:00</span>
          <span class="effect">Peak - Euphoria, hyperfocus, possible paranoia</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+2:00-6:00</span>
          <span class="effect">Comedown - Anxiety, depression, intense cravings</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+6:00-48:00</span>
          <span class="effect">After effects - Exhaustion, psychosis risk, sleep disruption</span>
        </div>
      </div>

      <div class="effects-categories">
        <div class="effect-category positive">
          <h4>‚úÖ Desired Effects (Low Doses)</h4>
          <ul>
            <li>Intense euphoria and confidence</li>
            <li>Extreme energy and alertness</li>
            <li>Enhanced focus and motivation</li>
            <li>Sociability and talkativeness</li>
            <li>Increased libido</li>
            <li>Feelings of invincibility</li>
          </ul>
        </div>
        
        <div class="effect-category negative">
          <h4>‚ùå Negative Effects & Dangers</h4>
          <ul>
            <li>Paranoia and delusions</li>
            <li>Violent behavior and aggression</li>
            <li>Hyperthermia (dangerous overheating)</li>
            <li>Rapid heart rate and hypertension</li>
            <li>Insomnia lasting days</li>
            <li>Compulsive, repetitive behaviors</li>
            <li>Hallucinations (visual, auditory, tactile)</li>
            <li>Dehydration and kidney damage</li>
          </ul>
        </div>
      </div>

      <div class="psychosis-warning">
        <h4>üß† Psychotic Episode Characteristics</h4>
        <ul>
          <li><strong>Delusions:</strong> Belief in persecution, surveillance, or superhuman abilities</li>
          <li><strong>Hallucinations:</strong> Seeing people, hearing voices, feeling bugs crawling</li>
          <li><strong>Bizarre behavior:</strong> Public nudity, climbing buildings, attacking others</li>
          <li><strong>Hyperthermia:</strong> Body temperature >104¬∞F, potentially fatal</li>
          <li><strong>Duration:</strong> Can last hours to days, sometimes requiring sedation</li>
        </ul>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>Œ±-PVP is a potent dopamine and norepinephrine reuptake inhibitor (NDRI) with some serotonin activity. Unlike cocaine, it has minimal affinity for sodium channels. The drug blocks dopamine and norepinephrine transporters (DAT and NET), causing accumulation of these neurotransmitters in synapses, particularly in reward pathways.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>DAT (Dopamine transporter)</strong></span>
            <span class="affinity">Very high affinity (IC50: ~10 nM)</span>
            <span class="function">Intense euphoria, reward, addiction potential</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>NET (Norepinephrine transporter)</strong></span>
            <span class="affinity">High affinity (IC50: ~50 nM)</span>
            <span class="function">Stimulation, alertness, cardiovascular effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>SERT (Serotonin transporter)</strong></span>
            <span class="affinity">Lower affinity (IC50: ~3000 nM)</span>
            <span class="function">Minimal empathogenic effects compared to MDMA</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Sodium channels</strong></span>
            <span class="affinity">Minimal affinity</span>
            <span class="function">No local anesthetic effects (unlike cocaine)</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Nicotinic receptors</strong></span>
            <span class="affinity">Some antagonist activity</span>
            <span class="function">May contribute to psychotic symptoms</span>
          </div>
        </div>

        <h4>Metabolism & Pharmacokinetics</h4>
        <div class="metabolism-details">
          <p><strong>Primary Pathway:</strong> Hepatic metabolism via CYP enzymes ‚Üí 2-oxo-PVP (inactive)</p>
          <p><strong>Half-life:</strong> 3-5 hours (highly variable by route and individual)</p>
          <p><strong>Bioavailability:</strong> ~70% oral, ~90% insufflated, ~95% vaporized</p>
          <p><strong>Peak plasma:</strong> 15-60 minutes (route dependent)</p>
          <p><strong>Excretion:</strong> Primarily renal, detectable in urine for 2-3 days</p>
          <p><strong>Active metabolites:</strong> Some metabolites may contribute to prolonged effects</p>
        </div>

        <h4>Neurotoxicity & Brain Changes</h4>
        <div class="neurotoxicity-info">
          <p><strong>Dopaminergic damage:</strong> Chronic use may damage dopamine neurons</p>
          <p><strong>Psychosis mechanism:</strong> Excessive dopamine in mesolimbic system</p>
          <p><strong>Hyperthermia:</strong> Dysregulation of temperature control centers</p>
          <p><strong>Cognitive impairment:</strong> Executive function deficits with chronic use</p>
          <p><strong>Structural changes:</strong> Potential brain atrophy with heavy use</p>
        </div>

        <h4>Addiction Pharmacology</h4>
        <ul>
          <li><strong>Reinforcement:</strong> Extremely high addiction potential due to DAT affinity</li>
          <li><strong>Tolerance:</strong> Develops rapidly, leading to dose escalation</li>
          <li><strong>Withdrawal:</strong> Severe depression, fatigue, intense cravings</li>
          <li><strong>Compulsive use:</strong> Strong urges to redose frequently</li>
          <li><strong>Cross-tolerance:</strong> With other stimulants, especially cathinones</li>
        </ul>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†Ô∏è Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Extreme Dangers</h4>
          <ul>
            <li><strong>Psychotic episodes:</strong> Violent, unpredictable behavior lasting hours/days</li>
            <li><strong>Hyperthermia:</strong> Fatal overheating, especially in hot environments</li>
            <li><strong>Cardiovascular collapse:</strong> Heart attack, stroke, arrhythmias</li>
            <li><strong>Kidney failure:</strong> Rhabdomyolysis from hyperthermia and dehydration</li>
            <li><strong>Addiction:</strong> Extremely rapid development of compulsive use</li>
            <li><strong>Overdose:</strong> Narrow margin between effects and toxicity</li>
          </ul>
        </div>
        
        <div class="safety-item precautions">
          <h4>üõ°Ô∏è Harm Reduction (If Use Occurs)</h4>
          <ul>
            <li>Never use alone - have sober supervision</li>
            <li>Start with minuscule doses (&lt;5mg)</li>
            <li>Avoid redosing - set strict limits beforehand</li>
            <li>Stay cool and hydrated</li>
            <li>Have benzodiazepines available for psychosis</li>
            <li>Avoid mixing with other stimulants or depressants</li>
            <li>Limit use to prevent rapid addiction</li>
          </ul>
        </div>
      </div>

      <div class="emergency-protocol">
        <h4>üö® Emergency Signs - Call 911 Immediately</h4>
        <ul>
          <li>Body temperature above 103¬∞F (39.4¬∞C)</li>
          <li>Violent or aggressive behavior</li>
          <li>Chest pain or difficulty breathing</li>
          <li>Seizures or convulsions</li>
          <li>Loss of consciousness</li>
          <li>Paranoid delusions or hallucinations</li>
          <li>Inability to recognize reality</li>
        </ul>
        <p><strong>For psychosis:</strong> Ensure safety, avoid restraints, speak calmly, get medical help immediately.</p>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏è Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Extremely Dangerous</h4>
          <ul>
            <li><strong>MAOIs:</strong> Hypertensive crisis, potentially fatal</li>
            <li><strong>Other stimulants:</strong> Extreme cardiovascular strain, psychosis risk</li>
            <li><strong>Tramadol:</strong> Seizure risk, serotonin syndrome</li>
            <li><strong>Tricyclic antidepressants:</strong> Cardiac arrhythmias</li>
            <li><strong>Cocaine:</strong> Additive cardiotoxicity</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° High Risk</h4>
          <ul>
            <li><strong>Alcohol:</strong> Masks intoxication, increases aggression</li>
            <li><strong>Benzodiazepines:</strong> May mask stimulant toxicity signs</li>
            <li><strong>Antipsychotics:</strong> May be necessary for psychosis but risky</li>
            <li><strong>Cannabis:</strong> May increase paranoia and psychosis risk</li>
          </ul>
        </div>
        
        <div class="interaction medical">
          <h4>üè• Medical Considerations</h4>
          <ul>
            <li><strong>Heart medications:</strong> Risk of dangerous interactions</li>
            <li><strong>Blood pressure meds:</strong> Œ±-PVP may override their effects</li>
            <li><strong>Psychiatric medications:</strong> Unpredictable interactions</li>
            <li><strong>Seizure medications:</strong> Œ±-PVP may lower seizure threshold</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏è Legal Status</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>üá∫üá∏ United States</h4>
            <p><strong>Schedule I</strong> - Illegal since 2014. Possession, manufacture, and distribution carry severe federal penalties. Often prosecuted under analog act even before scheduling.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¨üáß United Kingdom</h4>
            <p><strong>Class B</strong> - Controlled under Psychoactive Substances Act. Up to 5 years for possession, 14 years for supply.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá™üá∫ European Union</h4>
            <p><strong>Controlled</strong> - Banned in most EU countries. Listed as controlled substance by EMCDDA after widespread abuse.</p>
          </div>
          <div class="jurisdiction">
            <h4>üåè Global Status</h4>
            <p><strong>Widely banned</strong> - Controlled or banned in most countries due to public health crises and violent incidents.</p>
          </div>
        </div>
        
        <div class="legal-consequences">
          <h4>‚öñÔ∏è Legal Consequences</h4>
          <ul>
            <li><strong>Criminal charges:</strong> Drug possession, manufacturing, distribution</li>
            <li><strong>Enhanced penalties:</strong> Often treated as major felony due to dangers</li>
            <li><strong>Public safety charges:</strong> Additional charges for violent behavior</li>
            <li><strong>Civil liability:</strong> Responsibility for damages during psychotic episodes</li>
          </ul>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Culture</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1960s</span>
          <p>First synthesized as part of pharmaceutical research into stimulants</p>
        </div>
        <div class="history-event">
          <span class="year">2010</span>
          <p>Appears in "bath salts" mixtures, begins showing up in emergency rooms</p>
        </div>
        <div class="history-event">
          <span class="year">2012</span>
          <p>Miami "zombie attack" incident brings bath salts to national attention</p>
        </div>
        <div class="history-event">
          <span class="year">2013-2014</span>
          <p>"Flakka" epidemic in Florida - hundreds of psychotic episodes</p>
        </div>
        <div class="history-event">
          <span class="year">2014</span>
          <p>DEA emergency scheduling due to public health crisis</p>
        </div>
        <div class="history-event">
          <span class="year">2015-2016</span>
          <p>Global wave of bans following similar crises worldwide</p>
        </div>
      </div>

      <div class="cultural-impact">
        <h4>Media & Public Perception</h4>
        <p>Œ±-PVP became synonymous with "zombie drug" behavior after numerous incidents of users stripping naked, displaying superhuman strength, and engaging in bizarre violent behavior. The substance gained notoriety through viral videos and news coverage of emergency room visits and police encounters.</p>
        
        <h4>Public Health Crisis</h4>
        <p>The "flakka" epidemic of 2013-2015 overwhelmed emergency services in several US states. Hospitals reported unprecedented numbers of patients requiring restraint and sedation, leading to rapid policy responses and international scheduling.</p>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research & Medical Status</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Addiction Studies</h4>
          <p>Research into Œ±-PVP's extreme addiction potential focuses on its high DAT affinity and rapid tolerance development. Studies compare it to crack cocaine for reinforcement strength.</p>
        </div>
        
        <div class="research-item">
          <h4>Psychosis Mechanisms</h4>
          <p>Investigation into why Œ±-PVP causes more frequent and severe psychotic episodes than other stimulants. Research focuses on dopaminergic hyperstimulation patterns.</p>
        </div>
        
        <div class="research-item">
          <h4>Treatment Protocols</h4>
          <p>Development of emergency protocols for Œ±-PVP intoxication, including cooling methods, sedation approaches, and long-term addiction treatment.</p>
        </div>
        
        <div class="research-item">
          <h4>Forensic Analysis</h4>
          <p>Development of detection methods for law enforcement and medical settings. Research into post-mortem detection and toxicology patterns.</p>
        </div>
      </div>

      <div class="medical-uses">
        <h4>üè• Medical Uses</h4>
        <p><strong>None.</strong> Œ±-PVP has no accepted medical use and is considered to have high abuse potential with no therapeutic benefit. It is used only in research settings to study addiction and psychostimulant toxicity.</p>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Crisis & Emergency</h4>
        <ul>
          <li><strong>Emergency:</strong> Call 911 for psychotic episodes or overdose</li>
          <li><strong>Poison Control:</strong> 1-800-222-1222 (US)</li>
          <li><strong>Crisis Text Line:</strong> Text HOME to 741741</li>
          <li><a href="https://www.samhsa.gov/">SAMHSA</a> - Treatment locator</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Addiction Treatment</h4>
        <ul>
          <li><a href="https://www.crystalmethaddiction.org/">Crystal Meth Addiction</a> - Treatment resources</li>
          <li><a href="https://www.smartrecovery.org/">SMART Recovery</a> - Science-based recovery</li>
          <li><a href="https://na.org/">Narcotics Anonymous</a> - 12-step program</li>
          <li>Local detox and rehabilitation facilities</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Harm Reduction & Info</h4>
        <ul>
          <li><a href="https://www.erowid.org/">Erowid</a> - Experience reports and warnings</li>
          <li><a href="https://psychonautwiki.org/">PsychonautWiki</a> - Detailed information</li>
          <li><a href="https://www.bluelight.org/">Bluelight</a> - Harm reduction forum</li>
          <li>Local needle exchange and harm reduction services</li>
        </ul>
      </div>
    </div>
  </div>

  <div class="danger-warning-footer">
    <h3>üíÄ Final Warning</h3>
    <p>Œ±-PVP is one of the most dangerous recreational drugs ever synthesized. It has caused more emergency room visits, violent incidents, and deaths per user than almost any other substance. The drug's unpredictable nature means that even experienced users can suffer psychotic breaks, hyperthermia, or cardiovascular collapse. There is no "safe" way to use Œ±-PVP - the risk of permanent harm or death is present at any dose.</p>
    
    <p><strong>If you or someone you know is struggling with Œ±-PVP addiction, seek immediate professional help. This is not a substance that can be safely used recreationally under any circumstances.</strong></p>
  </div>

</div>
    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/Dyo-s-Dubious-Domain/js/lunr.min.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/search.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/substance-integration.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/profile.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/friends.js"></script>
</body>
</html>